Abstract
A recent set of questions and answers developed by FDA suggests that drug and device makers may be allowed to provide information, including pricing, on investigational products to health plan sponsors but not hospitals and health systems. FDA presented its “current thinking” on the subject of
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
